2 innovative scientific platforms

Ipsen has built two leading-edge technological platforms, toxins and peptides, fields in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of harnessing the synergies in toxins and peptides in hybrid molecules like targeted secretion inhibitors (TSI). With their unique properties, these molecules offer potential in the treatment of neuromuscular, endocrine and proliferative disorders, as well as for pain.

2

excellent technological platforms: toxins and peptides

13%

of sales invested in R&D in 2015

3 benchmark R&D centers

Ipsen has set-up its R&D centers at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. Each site is located close to leading academic research centers, cutting-edge medical centers and biotechnological companies. Interactions with key health industry players greatly increase our chances of access to innovative technologies to speed up the discovery and approval of drugs and services that improve the lives of patients.

Pipeline

Ipsen’s Research & Development comprises both new molecule development programs and lifecycle management programs for our existing products. During preclinical and clinical development, early identification of therapeutic targets and markers helps researchers to better define the potential value of molecules. This speeds up the process of drug development and drug approval application procedures.

Scientific affairs

Ipsen's active partnership policy underpins internal R&D, from fundamental research through to clinical development.
Last update 13/04/2017